Health
Omeros halts development of kidney disease therapy after study fails
Omeros Corp. said Monday it will stop developing an experimental therapy to treat a certain type of kidney disease after a late-stage study failed and
Italy will charge foreigners €2,000 a year for medical care
Foreigners living in Italy will be able to use the national health service after paying an annual fee of 2,000 euros ($2,109), the government said
Labcorp launches three-step blood test for Alzheimer’s disease
Labcorp has begun selling U.S. doctors the first test for three blood biomarkers they say can detect signs of Alzheimer’s disease, speeding diagnosis of the
FDA found no violations at trial sites regarding Pfizer’s Lyme disease vaccine
A U.S. health regulator found no violations at clinical centres run by Care Access for Pfizer and French partner Valneva in a trial of a
More than 7 million Americans have received updated COVID vaccines
According to the US Department of Health and Human Services, more than 7 million Americans have received the updated COVID-19 vaccines, despite reports that some
India clears cough syrup firm linked to Uzbek deaths
The northern Indian state of Uttar Pradesh has authorised the resumption of most of the production at a plant owned by Marion Biotech that made
Court approves Mallinckrodt restructuring and $1 billion cut in opioid reimbursement
Pharmaceutical company Mallinckrodt has received court approval for a bankruptcy plan that reduces by $1 billion the amount it owes to victims of the opioid
Drug maker GSK settles another lawsuit in California over heartburn drug Zantac
GSK on Wednesday said it would confidentially settle another lawsuit in California alleging that its discontinued heartburn drug Zantac caused cancer, as the British drugmaker
Alnylam refuses to expand the use of heart disease drugs in the U.S.
Alnylam Pharmaceuticals said it will not expand the use of its drug to treat a potentially fatal heart condition in the U.S. after the Food
The number of U.S. employers paying for weight-loss drugs could nearly double in 2024
The number of U.S. employers paying for obesity drugs, including Novo Nordisk’s Wegovy, which belongs to the GLP-1 class of drugs, could nearly double next